Tesamorelin × aminousa.com — lab test, November 2025
freedomdiagnosticstesting.com publishes a public verification portal. Any test attributed to this lab can be looked up and confirmed directly with the lab — so this result doesn't rest on our review alone.
This certificate carries no lookup code.
Test results
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
About this test
Label 10 mg · Lab measured 10.88 mg
109% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 2.7 mg using the measured mass, against 2.5 mg on the label — 9% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
Independent HPLC purity analysis of Tesamorelin from aminousa.com, performed by freedomdiagnosticstesting.com on November 6, 2025. Reported purity: 98.964%. Net content: 10.88 mg against 10 mg labeled (109% of label). Batch 25TESA10-0003. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Other lots of Tesamorelin from aminousa.com
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| 26TESA10-0003 | 7 Jan 2026 | freedomdiagnosticstesting.com | 99.138% | 121% | Unverified |
| 25TESA2-0003 | 22 Sept 2025 | BioRegen | 99.74% | 90% | Unverified |
| 25TESA5-0005 | 4 Sept 2025 | BioRegen | 99.9% | 107% | Unverified |
| 25TESA10-0002 | 23 Jul 2025 | BioRegen | 98.1% | 97% | Unverified |
| 25TESA5-0004 | 17 Jun 2025 | BioRegen | 99.78% | 93% | Unverified |
| 24TESA2-0002 | 28 Feb 2025 | BioRegen | 99.7% | 96% | Unverified |
| 25TESA10-0001 | 20 Jan 2025 | BioRegen | 99.83% | 100% | Unverified |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion